Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more

Conditions: Plaque-type Psoriasis
Interventions: CD 2027; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Hot Springs, Arizona • Austin, Texas • Bryan, Texas

Conditions: Psoriasis
Interventions: Methotrexate, Raptiva; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bexley, Ohio

Conditions: Psoriasis
Interventions: Skin Tape Stripping, Punch Biopsy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Psoriasis
Interventions: MEDI-522, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 18
States / cities: Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more

Conditions: Psoriasis
Interventions: Artificial intelligence, Human, Standard of Care; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriasis
Interventions: Otezla; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Psoriasis
Interventions: Internet Survey, fluocinonide 0.05% ointment; Behavioral · Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriatic Arthritis
Interventions: Diet 1, Diet 2; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Plaque Psoriasis
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: San Diego, California • North Logan, Connecticut • Miami, Florida + 15 more

Conditions: Psoriasis
Interventions: Placebo for Risankizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more

Conditions: Psoriasis (PsO)
Interventions: Deucravacitinib, Other systemic treatments for PsO; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Genital Psoriasis, Scalp Psoriasis
Interventions: Risankizumab, Placebo for Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Encino, California + 32 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more

Conditions: Plaque Psoriasis
Interventions: PF-04965842, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 35
States / cities: Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 28 more

Conditions: Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions: KPL-716, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more

Conditions: Psoriasis
Interventions: U0267, Vehicle; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 13
States / cities: San Diego, California • Denver, Colorado • Miami, Florida + 9 more

Conditions: Plaque Psoriasis
Interventions: Itacitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Hot Springs, Arkansas • Los Angeles, California • Clinton, Minnesota + 2 more

Conditions: Psoriasis
Interventions: Skin biopsy and blood test; Procedure
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Skin Tape Harvesting for Transcriptomics Analysis

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Assessing Psoriasis Treatment Outcomes

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Using an Internet Study to Improve Adherence for Psoriasis Patients

Diet Interventions in Psoriatic Arthritis

Understanding Participation Habits Among Plaque Psoriasis Patients

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

A Study to Assess Deucravacitinib Safety in Pregnancy

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Low Dose Naltrexone for Chronic Pain From Arthritis

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

Comparative Analysis of Small and Large Plaque Psoriasis